AR110790A1 - Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) - Google Patents
Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)Info
- Publication number
- AR110790A1 AR110790A1 ARP180100228A ARP180100228A AR110790A1 AR 110790 A1 AR110790 A1 AR 110790A1 AR P180100228 A ARP180100228 A AR P180100228A AR P180100228 A ARP180100228 A AR P180100228A AR 110790 A1 AR110790 A1 AR 110790A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- halogen
- heteroaryl
- halo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000004215 Carbon black (E152) Substances 0.000 title 1
- 229930195733 hydrocarbon Natural products 0.000 title 1
- 150000002430 hydrocarbons Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101150073096 NRAS gene Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto representado por la fórmula (1), un enantiómero, diastereómero, tautómero, solvato, prodroga o sal farmacéuticamente aceptable del mismo, en donde A y B están independientemente seleccionados a partir de arilo mono- o bicíclico de 6 a 10 miembros y heteroarilo mono- o bicíclico de 5 a 10 miembros que contiene 1 a 4 heteroátomos independientemente seleccionados a partir de N, O y S, en donde arilo y heteroarilo están no sustituidos o sustituidos con 1 a 7 sustituyentes independientemente seleccionados a partir del grupo que consiste en halógeno, OH, CN, C₁₋₆-alquilo, O-C₁₋₆-alquilo, C(O)ORᵃ, OC(O)Rᵃ, S(O)-C₁₋₆-alquilo, S(O)₂-C₁₋₆-alquilo, N(Rᵃ)₂, C(O)N(Rᵃ)₂, NRᵃC(O)-C₁₋₆-alquilo, S(O)₂N(Rᵃ)₂, NRᵃS(O)₂-C₁₋₆-alquilo y C₃₋₆-cicloalquilo, en donde el alquilo y el cicloalquilo están no sustituidos o sustituidos con 1 a 3 sustituyentes independientemente seleccionados a partir del grupo que consiste en halógeno, C₁₋₃-alquilo, halo-C₁₋₃-alquilo, OH, CN y oxo, o en donde dos sustituyentes en el grupo arilo o heteroarilo junto con los átomos a los que están unidos pueden formar un anillo carbocíclico o anillo heterocíclico de 5 a 7 miembros saturado o parcialmente insaturado, que contiene 1 a 3 heteroátomos independientemente seleccionados a partir de O, N y S, en donde el anillo carbocíclico o el anillo heterocíclico está no sustituido o sustituido con 1 a 5 sustituyentes independientemente seleccionados a partir del grupo que consiste en halógeno, C₁₋₆-alquilo y halo-C₁₋₆-alquilo; R¹, R², R³ están cada uno independientemente seleccionados a partir de hidrógeno, halógeno, C₁₋₃-alquilo, halo-C₁₋₃-alquilo, OH, O-C₁₋₃-alquilo, y CN; Rᵃ es hidrógeno o C₁₋₆-alquilo; y Rᵇ es hidrógeno o C₁₋₆-alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17000157 | 2017-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110790A1 true AR110790A1 (es) | 2019-05-02 |
Family
ID=57960222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100228A AR110790A1 (es) | 2017-02-01 | 2018-01-31 | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11376241B2 (es) |
| EP (1) | EP3577115B1 (es) |
| JP (1) | JP2020505467A (es) |
| KR (1) | KR20190113902A (es) |
| CN (1) | CN110234650A (es) |
| AR (1) | AR110790A1 (es) |
| AU (1) | AU2018216955B2 (es) |
| BR (1) | BR112019015704A2 (es) |
| CA (1) | CA3051034A1 (es) |
| CL (1) | CL2019002112A1 (es) |
| CO (1) | CO2019007882A2 (es) |
| CR (1) | CR20190393A (es) |
| CU (1) | CU20190067A7 (es) |
| EA (1) | EA201991600A1 (es) |
| EC (1) | ECSP19055179A (es) |
| IL (1) | IL268082A (es) |
| MX (1) | MX2019008993A (es) |
| NI (1) | NI201900075A (es) |
| PE (1) | PE20191479A1 (es) |
| PH (1) | PH12019550136A1 (es) |
| SG (1) | SG11201906959RA (es) |
| TW (1) | TWI674260B (es) |
| UA (1) | UA122746C2 (es) |
| UY (1) | UY37590A (es) |
| WO (1) | WO2018141855A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| JP7382348B2 (ja) | 2018-02-06 | 2023-11-16 | アイディアヤ バイオサイエンシーズ，インコーポレイティド | ＡｈＲモジュレータ |
| WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
| EP4003337A4 (en) | 2019-07-30 | 2023-06-28 | Oregon State University | Aryl hydrocarbon receptor activators |
| KR102351515B1 (ko) | 2019-12-17 | 2022-01-14 | (주)수파드엘릭사 | 아릴 탄화수소 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물 |
| EP4093739A1 (en) * | 2020-01-23 | 2022-11-30 | Phenex Pharmaceuticals AG | Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| EP4267131A4 (en) * | 2020-12-28 | 2025-04-23 | Celgene Corporation | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES |
| CN115572282B (zh) * | 2021-07-05 | 2024-07-09 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
| EP4602034A2 (en) * | 2022-10-14 | 2025-08-20 | Oregon State University | Selective modulators of ahr-regulated transcription and method for using such modulators to treat cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992002500A1 (fr) | 1990-07-31 | 1992-02-20 | Teikoku Hormone Mfg. Co., Ltd. | Derive de 2-phenylindole |
| DK0948495T3 (da) | 1996-11-19 | 2004-06-01 | Amgen Inc | Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler |
| WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| DE602006017741D1 (de) | 2005-11-18 | 2010-12-02 | Hoffmann La Roche | Azaindol-2-carboxamid-derivate |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US9144557B2 (en) | 2009-10-13 | 2015-09-29 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic small molecule compounds and their uses |
| CN106588908A (zh) * | 2009-11-02 | 2017-04-26 | 宋嘉声 | 用于介入治疗和根除癌症的ite |
| US20130338201A1 (en) * | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
| CN102834393B (zh) * | 2010-02-03 | 2015-07-22 | 武田药品工业株式会社 | 细胞凋亡信号调节激酶1抑制剂 |
| US8410117B2 (en) | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| WO2012015914A2 (en) | 2010-07-27 | 2012-02-02 | Trustees Of Boston University | Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
| GB201104267D0 (en) * | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| WO2014060328A1 (en) | 2012-10-17 | 2014-04-24 | F. Hoffmann-La Roche Ag | 6-aminoindole derivatives as trp channel antagonists |
| SMT201800230T1 (it) | 2012-12-21 | 2018-07-17 | Plexxikon Inc | Composti e metodi per la modulazione della chinasi e loro indicazioni |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| TW201835070A (zh) | 2017-02-21 | 2018-10-01 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
-
2018
- 2018-01-25 TW TW107102716A patent/TWI674260B/zh not_active IP Right Cessation
- 2018-01-31 AR ARP180100228A patent/AR110790A1/es unknown
- 2018-01-31 UY UY0001037590A patent/UY37590A/es unknown
- 2018-02-01 CA CA3051034A patent/CA3051034A1/en not_active Withdrawn
- 2018-02-01 KR KR1020197025765A patent/KR20190113902A/ko not_active Ceased
- 2018-02-01 SG SG11201906959RA patent/SG11201906959RA/en unknown
- 2018-02-01 AU AU2018216955A patent/AU2018216955B2/en not_active Ceased
- 2018-02-01 BR BR112019015704A patent/BR112019015704A2/pt not_active Application Discontinuation
- 2018-02-01 CR CR20190393A patent/CR20190393A/es unknown
- 2018-02-01 CN CN201880009290.2A patent/CN110234650A/zh not_active Withdrawn
- 2018-02-01 US US16/479,847 patent/US11376241B2/en active Active
- 2018-02-01 UA UAA201908355A patent/UA122746C2/uk unknown
- 2018-02-01 MX MX2019008993A patent/MX2019008993A/es unknown
- 2018-02-01 CU CU2019000067A patent/CU20190067A7/es unknown
- 2018-02-01 PE PE2019001483A patent/PE20191479A1/es unknown
- 2018-02-01 JP JP2019561369A patent/JP2020505467A/ja not_active Ceased
- 2018-02-01 WO PCT/EP2018/052538 patent/WO2018141855A1/en not_active Ceased
- 2018-02-01 EP EP18707242.6A patent/EP3577115B1/en active Active
- 2018-02-01 EA EA201991600A patent/EA201991600A1/ru unknown
-
2019
- 2019-07-15 NI NI201900075A patent/NI201900075A/es unknown
- 2019-07-15 IL IL268082A patent/IL268082A/en unknown
- 2019-07-23 CO CONC2019/0007882A patent/CO2019007882A2/es unknown
- 2019-07-24 PH PH12019550136A patent/PH12019550136A1/en unknown
- 2019-07-29 CL CL2019002112A patent/CL2019002112A1/es unknown
- 2019-07-31 EC ECSENADI201955179A patent/ECSP19055179A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3051034A1 (en) | 2018-08-09 |
| CO2019007882A2 (es) | 2019-10-09 |
| MX2019008993A (es) | 2019-12-19 |
| US20210260045A1 (en) | 2021-08-26 |
| NI201900075A (es) | 2019-10-30 |
| AU2018216955B2 (en) | 2020-09-17 |
| CU20190067A7 (es) | 2020-03-04 |
| EA201991600A1 (ru) | 2020-03-10 |
| SG11201906959RA (en) | 2019-08-27 |
| CR20190393A (es) | 2019-10-21 |
| EP3577115B1 (en) | 2020-12-02 |
| AU2018216955A1 (en) | 2019-08-01 |
| CN110234650A (zh) | 2019-09-13 |
| KR20190113902A (ko) | 2019-10-08 |
| CL2019002112A1 (es) | 2019-12-20 |
| UY37590A (es) | 2018-02-28 |
| PH12019550136A1 (en) | 2020-03-02 |
| US11376241B2 (en) | 2022-07-05 |
| EP3577115A1 (en) | 2019-12-11 |
| IL268082A (en) | 2019-09-26 |
| PE20191479A1 (es) | 2019-10-16 |
| TW201838991A (zh) | 2018-11-01 |
| UA122746C2 (uk) | 2020-12-28 |
| TWI674260B (zh) | 2019-10-11 |
| BR112019015704A2 (pt) | 2020-04-07 |
| ECSP19055179A (es) | 2019-08-30 |
| JP2020505467A (ja) | 2020-02-20 |
| WO2018141855A1 (en) | 2018-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR110790A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR110990A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR109349A1 (es) | Compuestos y usos | |
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR117617A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1 | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| AR100033A1 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| AR107973A1 (es) | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj | |
| AR096339A1 (es) | Agonistas del receptor de somatostatina subtipo 4 (sstr4) | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| MX2017011824A (es) | Derivado de morfinano. | |
| AR109735A1 (es) | Método para la síntesis de derivado de 3-fenil-2,3,4,8,9,10-hexahidropirano[2,3-f]cromeno e isómero óptico del mismo | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| AR101255A1 (es) | Derivados de isoindolinona | |
| AR109296A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| PE20221732A1 (es) | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR122703A1 (es) | Inhibidores de rip1k | |
| AR103414A1 (es) | Derivados de hidroxialquil-piperazina como moduladores del receptor cxcr3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |